Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 09/05/2025
Short Title (70 char) North American Custom Laboratories LLC dba FarmaKeio Superior Custom Compounding. Richardson, TX. 483 issued 09/05/2025
FEI Number 3014229024
Firm Name North American Custom Labo
Similar Posts
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic ActHintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
Learn more about recommendations for patients who are considering a Hintermann Series H3 TAR system or who have one; recommendations for health care providers.Current Good Manufacturing Practice for Medical Gases
Pharmaceutical Quality/Manufacturing Standards (CGMP)Qualified Clinical Outcome Assessments (COA)
The table below lists qualified Clinical Outcome Assessments (COA). The tables include legacy projects (those submitted prior to passage of the 21st Century Cures Act), as well as those submitted as part of the newer section 507 process (referring to section 507 of the Federal Food, Drug and CosmetiEndoscopic Aspiration Needle Recall: Olympus Removes Certain ViziShot 2 FLEX (19G) Needles Due to Potentially Deformed A-traumatic Tips
Certain lots of ViziShot 2 FLEX (19G) aspiration needles may have deformed a-traumatic tips that pose a risk to patient safety if they are used.FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).